Quantisnow Logo
Dashboard
Subscribe to $TTNP

Titan Pharmaceuticals Inc.

$TTNP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

IPO Year:

Exchange: NASDAQ

Website: titanpharm.com

Peers

$AERI
$CTXR
$SPPI
$TMDI

Recent Analyst Ratings for Titan Pharmaceuticals Inc.

DatePrice TargetRatingAnalyst
See more ratings

Titan Pharmaceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

See more

  • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

    NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.

    NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the "Merger Agreement") regarding a business combination with KE Sdn. Bhd. ("KE"). The Merger Agreement was approved by Titan's board of directors (the "Board"). If the Merger Agreement is approved by the stockholders of Titan and KE (and the other closing conditions are satisfied or waived in accordance with the Merger Agreement), and upon consummation of the transactions contemplated by the Merger Agreement (the "Closing"), Titan will be combined with KE in a "reverse merger" transaction consisting

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

    SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market. As such, the listing matter has been closed.  About Titan Pharmaceuticals Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with utilizing ProNeura® long-term, conti

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

    SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock, which will be effective following the filing of an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Amendment"). The Company's stockholders approved the reverse stock split at a Special Meeting of Stockholders on December 27, 2023. The Company's shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market following the filing of the Amendment, which is intended go effective on January 9, 20

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

    SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

    SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the "Purchase Agreement") with The Sire Group Ltd. ("Sire Group") for the sale of the Company's newly designated Series AA Convertible Preferred Stock (the "Preferred Stock"). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i) $5 million in cash at closing and (ii) $4.5 million in the form of a promissory note from Sire Group, personally guaranteed by a principal of Sire Group, due and payable on September 23, 2023, subje

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

    SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the "Agreement") with Fedson, Inc., a Delaware Corporation ("Fedson"), for the sale of certain ProNeura assets including Titan's portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology. The Company's addiction portfolio consists of the Probuphine and Nalmefene implant programs.  Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Provides Shareholder Update

    Signs Non-Binding Letter of Intent for Transformational TransactionContinues to Make Substantial Progress on Strategic Transactions Including Sale of Existing Assets SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to complete a reverse merger with a leading developer in Advanced Air Mobility (AAM) (the "Proposed Reverse Merger"). Titan Chief Executive Officer, David E. Lazar, commented, "We believe that the Advanced Air Mobility sector offers a potential tremendous growth opportunity for our shareholders. I am encouraged by our recent advancements

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

    SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix Inc. ("Ocular") pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States. Under the terms of the agreement, Ocular will pay Titan an upfront licensing fee with the potential for additional payments upon reaching certain milestones. Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan Pharmaceuticals, commented, "We are pleased to enter into this licensing agreement with Ocular. Our team has been

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces Board Expansion and Management Changes

    SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Board") from five (5) to eleven (11) and appointed six new directors following their election at its special meeting of stockholders held on August 15, 2022 (the "Special Meeting"). The new directors, which were on a nominee slate proposed by Activist Investing LLC (together with its affiliates, "Activist Investing"), are Avraham Ben-Tzvi, Peter L. Chasey, Eric Greenberg, David E. Lazar, Matthew C. McMurdo and David Natan. In addition, following the Special Meeting, Mr. Lazar was appointed interim Cha

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

Titan Pharmaceuticals Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Titan Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Titan Pharmaceuticals Inc. SEC Filings

See more

Titan Pharmaceuticals Inc. Leadership Updates

Live Leadership Updates

See more

  • Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

    NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan") today reported that it received a notice (the "5250 Notice") on November 22, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) ("Rule 5250") as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Q3 Form 10-Q") in a timely manner. Under Nasdaq rules, the Company has 60 calendar days from receipt of the 5250 Notice or until January 21, 2025, to submit a plan to

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

    SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam to the Company's Board of Directors, effective October 12, 2023. Mr. Shen has also been appointed Chairman of the Board. Simultaneous with the election of Mr. Shen and Mr. Chiam to the Board, David E. Lazar and Peter L. Chasey each submitted their resignations from the Board, effective immediately. These resignations were not the result of any disagreements with the Company relating to the Company's operations, policies or practices. Mr. Lazar will remain with the Company as Chief Execut

    $TTNP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

Titan Pharmaceuticals Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more